COMMUNIQUÉS West-GlobeNewswire

Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System
17/03/2025
DeepView ® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance Spectral AI plans FDA submission by mid [...]
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
17/03/2025
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives [...]
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17/03/2025
WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
17/03/2025
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton’s tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary [...]
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
17/03/2025
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
17/03/2025
Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without any modification; [...]
Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
17/03/2025
March 17 th , 2025 Taiho Pharmaceutical Co., Ltd. Araris Biotech AG Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho [...]
Anocca Announces Authorisation of Clinical Trial Application to Start First In-Human Trial in Advanced Pancreatic Cancer
17/03/2025
CTA approval marks Anocca’s transition to a clinical-stage company First-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced Pancreatic Cancer at leading medical centres in Sweden, Denmark, Germany [...]
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform
17/03/2025
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody ® Pipeline and Platform Financing led by General Catalyst with additional investment from new [...]
Celex Oncology Announce Novel Mechanism in Cancer Care and Attendance at Bio-Europe Spring 2025
17/03/2025
LONDON, March 17, 2025 (GLOBE NEWSWIRE) -- Celex Oncology, a UK biotechnology company founded in 2017 and on the brink of launching the fourth revolution in cancer care, today announced the Celex model and investigative [...]
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
17/03/2025
Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 [...]
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
17/03/2025
Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA , a biotechnology company [...]
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
17/03/2025
Ad hoc announcement pursuant to Art. 53 LR FDA confirms that prescribers and pharmacists are no longer expected to interact with the REMS Allschwil, Switzerland – March 17, 2025 Idorsia Ltd (SIX: IDIA) today announced [...]
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
17/03/2025
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA) Late-breaking oral on Elevidys’ [...]
Global Reach for US Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites
17/03/2025
TAIPEI, Taiwan and ADELAIDE, Australia, March 17, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech [...]
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
17/03/2025
- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 - - Potential for Biologics License Application submission for [...]
DentPure Under Review: How Probiotics Help Support Stronger Teeth & Healthier Gums
16/03/2025
Harnessing the Power of Probiotics to Combat Bad Breath, Strengthen Enamel, and Support Optimal Oral Health AURORA, Colo., March 16, 2025 (GLOBE NEWSWIRE) -- In an era where oral care is evolving beyond traditional [...]
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
15/03/2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE [...]
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
15/03/2025
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective [...]

Pages